Table 3.
Unadjusted Analyses of pre-transplant depression and clinical outcomes of autologous and allogeneic HCT recipients
| Outcome | No Depression | History of depression | P-value | ||
|---|---|---|---|---|---|
| N | (95% CI) | N | (95% CI) | ||
| Allogenic HCT | |||||
|
| |||||
| Overall-survival | 6317 | 1116 | *<0.001 | ||
| 1-year | 60 (59-62) | 57 (54-60) | 0.03 | ||
| 3-year | 45 (44-47) | 40 (37-43) | 0.002 | ||
|
| |||||
| II-IV acute GVHD | 6299 | 1115 | <0.001 | ||
| 100-day | 39 (38-40) | 46 (43-49) | |||
|
| |||||
| III-IV acute GVHD | 6306 | 1115 | 0.19 | ||
| 100-day | 17 (16-18) | 19 (17-21) | |||
|
| |||||
| Chronic GVHD | 6200 | 1109 | *0.57 | ||
| 1-year | 43 (42-44) | 43 (40-46) | 0.93 | ||
| 3-year | 49 (48-51) | 50 (47-53) | 0.80 | ||
|
| |||||
| Moderate-severe chronic GVHD | 6234 | 1112 | *0.05 | ||
| 1-year | 23 (22-24) | 25 (23-28) | 0.13 | ||
| 3-year | 26 (25-27) | 28 (26-31) | 0.07 | ||
|
| |||||
| Autologous HCT | N | (95% CI) | N | (95% CI) | P-value |
|
| |||||
| Overall-survival | 3274 | 512 | *0.04 | ||
| 1-year | 89 (87-90) | 87 (84-90) | 0.30 | ||
| 3-year | 73 (72-75) | 67 (63-72) | 0.01 | ||
| 4-year | 67 (65-69) | 62 (57-66) | 0.04 | ||
*
Overall p-value produced by log-rank or Gray’s test.